Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

In the Pursuit of Excellence: Reflections From the Editor-in-Chief of Journal of Clinical Oncology.

Cannistra SA.

J Clin Oncol. 2016 Sep 12. pii: JCO696070. [Epub ahead of print] No abstract available.

PMID:
27621398
2.

Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer.

Liu JF, Cannistra SA.

J Clin Oncol. 2014 May 1;32(13):1287-9. doi: 10.1200/JCO.2013.54.7299. Epub 2014 Mar 17. No abstract available.

PMID:
24637996
3.

Reply to C.M. Booth et al.

Goodwin PJ, Ballman KV, Small EJ, Levine M, Cannistra SA.

J Clin Oncol. 2013 Sep 10;31(26):3300. doi: 10.1200/JCO.2013.51.8241. Epub 2013 Aug 12. No abstract available.

PMID:
23943837
4.

Evaluation of treatment benefit in Journal of Clinical Oncology.

Goodwin PJ, Ballman KV, Small EJ, Cannistra SA.

J Clin Oncol. 2013 Mar 20;31(9):1123-4. doi: 10.1200/JCO.2012.47.6952. Epub 2013 Jan 28. No abstract available.

PMID:
23358984
5.

Bevacizumab rechallenge after first line maintenance bevacizumab.

Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA.

Gynecol Oncol. 2012 May;125(2):510-1. doi: 10.1016/j.ygyno.2012.02.013. Epub 2012 Feb 21. No abstract available.

PMID:
22366591
6.

Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial.

Konstantinopoulos PA, Cannistra SA.

J Clin Oncol. 2012 Feb 1;30(4):347-50. doi: 10.1200/JCO.2011.40.1489. Epub 2011 Dec 27. No abstract available.

PMID:
22203759
7.

Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer.

Janco JM, Hacker MR, Konstantinopoulos PA, Cannistra SA, Awtrey CS.

J Minim Invasive Gynecol. 2011 Sep-Oct;18(5):629-33. doi: 10.1016/j.jmig.2011.06.005. Epub 2011 Jul 30.

PMID:
21803662
8.

Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL, Cannistra SA.

Cancer Res. 2011 Aug 1;71(15):5081-9. doi: 10.1158/0008-5472.CAN-10-4668. Epub 2011 Jun 15.

9.

New initiatives at Journal of Clinical Oncology.

Cannistra SA.

J Clin Oncol. 2011 Jul 1;29(19):2609-10. doi: 10.1200/JCO.2011.36.7631. Epub 2011 Jun 6. No abstract available.

PMID:
21646608
10.

Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer.

Konstantinopoulos PA, Cannistra SA, Fountzilas H, Culhane A, Pillay K, Rueda B, Cramer D, Seiden M, Birrer M, Coukos G, Zhang L, Quackenbush J, Spentzos D.

PLoS One. 2011 Mar 29;6(3):e18202. doi: 10.1371/journal.pone.0018202.

11.

Phase I studies of drug combinations.

Verweij J, Disis ML, Cannistra SA.

J Clin Oncol. 2010 Oct 20;28(30):4545-6. doi: 10.1200/JCO.2010.30.6282. Epub 2010 Sep 20. No abstract available.

PMID:
20855831
12.

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA.

J Clin Oncol. 2010 Aug 1;28(22):3555-61. doi: 10.1200/JCO.2009.27.5719. Epub 2010 Jun 14. Erratum in: J Clin Oncol. 2010 Nov 10;28(32):4868.

13.

Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

Cannistra SA.

J Clin Oncol. 2010 Jul 1;28(19):3101-3. doi: 10.1200/JCO.2010.29.7077. Epub 2010 Jun 1. No abstract available.

PMID:
20516442
14.

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.

Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM.

J Clin Oncol. 2010 Jan 1;28(1):154-9. doi: 10.1200/JCO.2009.22.7900. Epub 2009 Nov 16.

PMID:
19917843
15.

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.

Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT.

J Clin Oncol. 2009 Nov 20;27(33):5601-6. doi: 10.1200/JCO.2009.23.2777. Epub 2009 Oct 13.

16.

Phase II trials in journal of clinical oncology.

Cannistra SA.

J Clin Oncol. 2009 Jul 1;27(19):3073-6. doi: 10.1200/JCO.2009.23.1811. Epub 2009 May 18. No abstract available.

PMID:
19451415
17.

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer.

Konstantinopoulos PA, Fountzilas E, Pillay K, Zerbini LF, Libermann TA, Cannistra SA, Spentzos D.

BMC Med Genomics. 2008 Nov 28;1:59. doi: 10.1186/1755-8794-1-59.

18.

Challenges and pitfalls of combining targeted agents in phase I studies.

Cannistra SA.

J Clin Oncol. 2008 Aug 1;26(22):3665-7. doi: 10.1200/JCO.2008.17.2676. No abstract available.

PMID:
18669449
19.

Gene-expression profiling in epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Cannistra SA.

Nat Clin Pract Oncol. 2008 Oct;5(10):577-87. doi: 10.1038/ncponc1178. Epub 2008 Jul 22. Review.

PMID:
18648354
20.

BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease.

Cannistra SA.

Clin Cancer Res. 2007 Dec 15;13(24):7225-7. No abstract available.

21.

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W.

J Clin Oncol. 2007 Nov 20;25(33):5180-6. Erratum in: J Clin Oncol. 2008 Apr 1;26(10):1773.

PMID:
18024865
22.

IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.

Spentzos D, Cannistra SA, Grall F, Levine DA, Pillay K, Libermann TA, Mantzoros CS.

Endocr Relat Cancer. 2007 Sep;14(3):781-90.

24.

Performance of biopsies in clinical research.

Cannistra SA.

J Clin Oncol. 2007 Apr 10;25(11):1454-5. No abstract available.

PMID:
17416872
25.

Gynecologic oncology or medical oncology: what's in a name?

Cannistra SA.

J Clin Oncol. 2007 Apr 1;25(10):1157-9. No abstract available.

PMID:
17401003
26.

Human semen refrigeration at + 4 degrees C: bio-kinetic characteristics.

Dondero F, Rossi T, Delfino M, Imbrogno N, Cannistrà S, Mazzilli F.

Cell Tissue Bank. 2006;7(1):61-4.

PMID:
16511666
27.

Intraperitoneal chemotherapy comes of age.

Cannistra SA.

N Engl J Med. 2006 Jan 5;354(1):77-9. No abstract available.

PMID:
16394306
28.

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA.

J Clin Oncol. 2005 Nov 1;23(31):7911-8. Epub 2005 Oct 3.

PMID:
16204010
29.

Advances in the management of epithelial ovarian cancer.

Berkenblit A, Cannistra SA.

J Reprod Med. 2005 Jun;50(6):426-38. Review.

PMID:
16050567
30.

Cancer of the ovary.

Cannistra SA.

N Engl J Med. 2004 Dec 9;351(24):2519-29. Review. No abstract available. Erratum in: N Engl J Med. 2005 Jan 6;352(1):104.

PMID:
15590954
31.

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA.

Gynecol Oncol. 2004 Dec;95(3):624-31.

PMID:
15581974
32.

Gene expression signature with independent prognostic significance in epithelial ovarian cancer.

Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA.

J Clin Oncol. 2004 Dec 1;22(23):4700-10. Epub 2004 Oct 25. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15505275
33.

The ethics of early stopping rules: who is protecting whom?

Cannistra SA.

J Clin Oncol. 2004 May 1;22(9):1542-5. No abstract available.

PMID:
15117977
34.

Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.

Berkenblit A, Tung N, Kim Y, Feyler H, Niloff J, Berghe KV, Cannistra SA.

Gynecol Oncol. 2003 Jun;89(3):486-93.

PMID:
12798716
35.

Progress in the management of gynecologic cancer: consensus summary statement.

Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP 3rd, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L.

J Clin Oncol. 2003 May 15;21(10 Suppl):129s-132s. No abstract available.

PMID:
12743127
36.

Granulosa cell tumor of the ovary.

Schumer ST, Cannistra SA.

J Clin Oncol. 2003 Mar 15;21(6):1180-9. Review.

PMID:
12637488
37.
38.

Diagnostic dilemmas in oncology: case 2. Dermatomyositis and ovarian cancer.

Raffel GD, Gravallese EM, Schwab P, Joseph JT, Cannistra SA.

J Clin Oncol. 2001 Dec 1;19(23):4341-3. No abstract available.

PMID:
11731518
39.

Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases.

Smith WM, Zhou XP, Kurose K, Gao X, Latif F, Kroll T, Sugano K, Cannistra SA, Clinton SK, Maher ER, Prior TW, Eng C.

Hum Genet. 2001 Aug;109(2):146-51.

PMID:
11511919
41.

When is a "prognostic factor" really prognostic?

Cannistra SA.

J Clin Oncol. 2000 Nov 15;18(22):3745-7. No abstract available.

PMID:
11078486
42.

Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity.

Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, Kufe D.

J Immunol. 2000 Aug 1;165(3):1705-11.

43.

Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.

Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden M, Kim Y, Niloff J, Cannistra SA.

Gynecol Oncol. 2000 May;77(2):271-7.

PMID:
10785477
44.

Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro.

Strobel T, Cannistra SA.

Gynecol Oncol. 1999 Jun;73(3):362-7.

PMID:
10366461
45.

In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene.

Tai YT, Strobel T, Kufe D, Cannistra SA.

Cancer Res. 1999 May 1;59(9):2121-6.

46.

Back to the future: multiagent chemotherapy in ovarian cancer revisited.

Cannistra SA.

J Clin Oncol. 1999 Mar;17(3):741-3. No abstract available.

PMID:
10071260
47.

BAD partly reverses paclitaxel resistance in human ovarian cancer cells.

Strobel T, Tai YT, Korsmeyer S, Cannistra SA.

Oncogene. 1998 Nov 12;17(19):2419-27.

48.
49.

BAX protein expression and clinical outcome in epithelial ovarian cancer.

Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA.

J Clin Oncol. 1998 Aug;16(8):2583-90. Erratum in: J Clin Oncol 1998 Sep;16(9):3211.

PMID:
9704707
50.

Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin.

Fink D, Nebel S, Norris PS, Baergen RN, Wilczynski SP, Costa MJ, Haas M, Cannistra SA, Howell SB.

Int J Cancer. 1998 Aug 31;77(5):741-6.

Supplemental Content

Loading ...
Support Center